Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 May;185(3):480-491.
doi: 10.1111/bjh.15805. Epub 2019 Feb 22.

Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population

Laura Magnano  1   2 , Sara Alonso-Alvarez  3 , Miguel Alcoceba  2   3 , Alfredo Rivas-Delgado  1   2 , Anna Muntañola  4 , Ferran Nadeu  5 , Xavier Setoain  6 , Sonia Rodríguez  6 , Marcio Andrade-Campos  7 , Natalia Espinosa-Lara  7 , Guillermo Rodríguez  8 , Juan Manuel Sancho  9 , Miriam Moreno  9 , Santiago Mercadal  10 , Itziar Carro  10 , Antonio Salar  11 , Francesc Garcia-Pallarols  11 , Reyes Arranz  12 , Jimena Cannata  12 , María J Terol  13 , Ana I Teruel  13 , Ana Jiménez-Ubieto  14 , Antonia Rodriguez  14 , Sonia González de Villambrosía  15 , José L Bello  16 , Lourdes López  17 , Silvana Novelli  18 , Erik de Cabo  19 , María E Infante  20 , Emilia Pardal  21 , Silvia Monsalvo  22 , Marcos González  2   3 , Alejandro Martín  2   3 , M Dolores Caballero  1   2 , Armando López-Guillermo  1   2 ; Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea (GELTAMO)
Affiliations
Free article
Clinical Trial

Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population

Laura Magnano et al. Br J Haematol. 2019 May.
Free article

Abstract

The use of immunochemotherapy has improved the outcome of follicular lymphoma (FL). Recently, complete response at 30 months (CR30) has been suggested as a surrogate for progression-free survival. This study aimed to analyse the life expectancy of FL patients according to their status at 30 months from the start of treatment in comparison with the sex and age-matched Spanish general population (relative survival; RS). The training series comprised 263 patients consecutively diagnosed with FL in a 10-year period who needed therapy and were treated with rituximab-containing regimens. An independent cohort of 693 FL patients from the Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea (GELTAMO) group was used for validation. In the training cohort, 188 patients were in CR30, with a 10-year overall survival (OS) of 53% and 87% for non-CR30 and CR30 patients, respectively. Ten-year RS was 73% and 100%, showing no decrease in life expectancy for CR30 patients. Multivariate analysis indicated that the FL International Prognostic Index was the most important variable predicting OS in the CR30 group. The impact of CR30 status on RS was validated in the independent GELTAMO series. In conclusion, FL patients treated with immunochemotherapy who were in CR at 30 months showed similar survival to a sex- and age-matched Spanish general population.

Keywords: complete response; follicular lymphoma; survival.

PubMed Disclaimer